Pfizer hit by UK Supreme Court ruling on Lyrica patent
European regulators have already restricted use
Mylan takes aim at Allergan’s off-patent blockbuster
Companies want Vraylar as option bipolar depression
R&D chief Michael Hayden to leave at year end.
Federal court throws out patents on Restasis